ArticleHaematologica2025
Recipient sex and donor leukemic cell characteristics determine leukemogenesis in patient-derived models.
Article in Haematologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ficoll-based isolation biases the profiling of immune cells and leukemic blasts in AML samples.Frontiers in immunology · 2026Article
- Context and timing matters in acute myeloid leukemia: females are the superior hosts.Haematologica · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In acute myeloid leukemia (AML), leukemogenesis depends on cell-intrinsic genetic aberrations and, therefore, studies on AML require investigations in an in vivo setting as provided by patient-derived xenograft (PDX) models. Here we report that, next to leukemic cell characteristics, recipient sex strongly influences the outgrowth of AML cells in PDX models, with females being much better repopulated than males in primary as well as secondary transplantation assays. Testosterone may be the more important player since, strikingly, better engraftment was seen in castrated male recipients than in control ones, while ovariectomy did not significantly impair engraftment in females. Shorter time to engraftment and mouse survival were observed in cases with adverse molecular risk, and respectively with a high ratio of FLT3-ITD mutated AML cells. Furthermore, cases of adverse-risk AML showed higher percentages of phenotypic leukemic stem cells, suggesting impaired differentiation capacity in these AML subtypes. Overall, we achieved successful repopulation with 14/23 (61%) favorable-risk, 18/30 (60%) intermediate-risk and 4/8 (50%) adverse-risk AML cases in female recipient PDX models. Our data identify recipient sex as an important experimental confounder in leukemia PDX models, and the contribution of the sex hormones to leukemogenesis as an intriguing, underexplored area for research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.